Clinical trials: Nonvalvular Atrial Fibrillation
Atrial Fibrillation
Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey
This is a national, multi-center, prospective study to evaluate the safety of Edoxaban in patients diagnosed with AF who are currently using Edoxaban for stroke prevention.
- Trial name
- ETAF-TR (NCT04594915)
- Testing
- Edoxaban
- Where
- 45 sites in Turkey (Türkiye)
- Volunteers
- 1,053 people
- Sponsor
- Daiichi Sankyo Turkey, a Daiichi Sankyo Company
Anticoagulation
A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark
The purpose of this study is to describe the characteristics of patients treated with different OATs and whether these characteristics differ between treatments.
- Trial name
- NCT02591732
- Where
- Denmark
- Volunteers
- 52,178 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
A study for subjects with atrial fibrillation (AF) or atrial flutter who are diagnosed with left atrial (LA) or left atrial appendage (LAA) thrombus. The study will assign subjects to rivaroxaban for treatment of thrombi.
- Trial name
- X-TRA (NCT01839357)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 31 sites in Bulgaria, France and 5 more
- Volunteers
- 60 people
- Sponsor
- Bayer
Atrial Fibrillation
Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical Outcomes
Atrial fibrillation is when the heart's two upper chambers (called atria) beat chaotically and irregularly, out of coordination with the two lower chambers (called ventricles) of the heart.
- Trial name
- NCT02964949
- Testing
- Edoxaban
- Where
- 233 sites in Belgium, Bulgaria and 13 more
- Volunteers
- 607 people
- Sponsor
- Daiichi Sankyo
Atrial Fibrillation
Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
The purpose of this study is to compare edoxaban to warfarin (with enoxaparin, if needed). It will see if edoxaban prevents stroke and other blood clotting problems as well and as safely as warfarin.
- Trial name
- ENSURE-AF (NCT02072434)
- Testing
- Edoxaban, Warfarin, Enoxaparin
- Where
- 228 sites in United States, Austria and 17 more
- Volunteers
- 2,199 people
- Sponsor
- Daiichi Sankyo
Nonvalvular Atrial Fibrillation
Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation
The main purpose of this study is to provide dose-guiding information by assessing the safety and tolerability of 4 different dosing regimens of an extended-release (ER) formulation of AZD0837 compared with well-controlled…
- Trial name
- NCT00684307
- Testing
- AZD0837, Vitamin-K antagonist at INR 2-3
- Volunteers
- 1,084 people
- Sponsor
- AstraZeneca
Atrial Fibrillation, Stroke
Using Left Atrium Appendage Closure in NVAF Patients With High Risk of Ischemic Stroke
To evaluate the safety and efficacy of using Microport CardioAdvance Left Atrium Appendage Closure for preventing stroke in Non-valvular atrial fibrillation (NVAF) patients who have contraindications for long-term…
- Trial name
- SAFE-PROTECT (NCT04479722)
- Testing
- Left atrial appendage closure procedure
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Atrial Fibrillation
Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation
In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the Non-valvular Atrial Fibrillation (NVAF) indication, Daiichi-Sankyo proposed this post-authorization safety study (PASS) to gain…
- Trial name
- ETNA-AF-EU (NCT02944019)
- Testing
- Edoxaban
- Where
- 724 sites in Austria, Belgium and 8 more
- Volunteers
- 13,980 people
- Sponsor
- Daiichi Sankyo
Nonvalvular Atrial Fibrillation
First in Man Study of Left Atrial Appendage Pulsed Field Ablation Occluder
This is the first in man study of E-SeaLATM developed and manufactured by Hangzhou Dinova EP Technology Co., Ltd, which can achieve pulsed field ablation and mechanical closure of the Left Atrial Appendage simultaneously, this…
- Trial name
- NCT05731882
- Testing
- E-SeaLA, CardioPulse PFA system
- Where
- 3 sites in China
- Volunteers
- 10 people
- Sponsor
- Hangzhou Dinova EP Technology Co., Ltd
Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke
Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)
This is a national, multicenter, cross-sectional, observational study within a convenience sample of Internal Medicine departments from 100 hospitals in Spain which agree to participate in the study.
- Trial name
- NCT02447341
- Where
- Spain
- Volunteers
- 987 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Anticoagulants Comparative Benefit-risk Ratio in Real Life
The study is an analysis using the French national health insurance database, six months after the beginning of NOAC launch in the NVAF indication.
- Trial name
- NCT02785354
- Where
- France
- Volunteers
- 103,101 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
National Institute of Health and Care Excellence (NICE) guidance recommends anticoagulation for stroke prevention in high risk patients with nonvalvular atrial fibrillation (AF).
- Trial name
- NCT05262322
- Testing
- Edoxaban, Apixaban, Rivaroxaban
- Where
- 8 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company
Persistent or Permanent Nonvalvular Atrial Fibrillation
Long-term Safety in Atrial Fibrillation Patients
The purpose of this study is to provide safety and tolerability data for AZD0837 during long-term treatment (5 years) in patients with non-valvular atrial fibrillation (AF) and one or more additional risk factors for stroke and…
- Trial name
- NCT00645853
- Testing
- AZD0837, VKA INR 2-3
- Volunteers
- 523 people
- Sponsor
- AstraZeneca
Atrial Fibrillation
Evaluation of the Safety and Efficacy of a Novel SeaLA™ Left Atrial Appendage Occluder
This study adapted a prospective, multicenter single-group objective performance criteria design. A total of 163 patients with non-valvular atrial fibrillation were enrolled in the clinical trial，follow up were scheduled in 7…
- Trial name
- NCT05911685
- Testing
- SeaLA™ left atrial appendage occluder
- Where
- China
- Volunteers
- 163 people
- Sponsor
- Hangzhou Dinova EP Technology Co., Ltd
Nonvalvular Atrial Fibrillation
Apixaban Safety and Therapy Adherence in Patients With Atrial Fibrillation
The aim of this observational study is to evaluate safety and therapeutic adherence during anticoagulant prophylaxis with apixaban in patients with nonvalvular atrial fibrillation.
- Trial name
- NCT07458191
- Testing
- Apixaban
- Where
- Bosnia and Herzegovina
- Volunteers
- 800 people
- Sponsor
- Bosnalijek D.D
Nonvalvular Atrial Fibrillation
Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients
The overall goal of this study was to evaluate the comparative safety and effectiveness of rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) across risk…
- Trial name
- NCT03374540
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- United States
- Volunteers
- 78,517 people
- Sponsor
- Bayer
Atrial Fibrillation
Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial (LA) or LA Appendage (LAA) Thrombus in Patients With Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter After Standard of Care (SoC) Anticoagulant Therapy
Thrombus outcome data will be collected retrospectively during 2011-2012 as a historical baseline of SoC with oral VKA (Vitamin K Antagonist(s) for the treatment of patients with nonvalvular AF or atrial flutter documented with…
- Trial name
- CLOT-AF (NCT01928979)
- Testing
- no drug
- Where
- 7 sites in Bulgaria, France and 5 more
- Volunteers
- 160 people
- Sponsor
- Bayer
Nonvalvular Atrial Fibrillation
Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the US
The overall objective of this proposal is to execute a real-world database analysis to evaluate hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients in the U.S Primary objective: To determine…
- Trial name
- NCT02674594
- Volunteers
- 30,000 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment
To describe the direct costs related to warfarin/apixaban treatment
- Trial name
- NCT04435769
- Where
- Czechia
- Volunteers
- 109 people
- Sponsor
- Pfizer
Atrial Fibrillation
Health-related Quality of Life in Patients on Anticoagulants
The present study has been designed to describe the health-related quality of life in patients with non valvular atrial fibrillation who have been prescribed a specific anticoagulant treatment for their non valvular atrial…
- Trial name
- RE-QUOL (NCT03134911)
- Testing
- DOAC or VKA, VKA
- Where
- 39 sites in Spain
- Volunteers
- 535 people
- Sponsor
- Boehringer Ingelheim